Log in to your Inderes Free account to see all free content on this page.
Pharma Equity Group
0.29 DKK -3.33%HC Andersen Capital receives payment from Pharma Equity Group for a DigitalIR/Corporate Visibility agreement. See disclaimer.
12 investors are following this company
Pharma Equity Group develops new medicines for the local treatment of serious and life-threatening inflammatory diseases for which there is currently no adequate treatment. The company uses repositioning of existing drugs and brings drug candidates to a clinical phase III stage, after which it is handed over to a strategic partner who will complete the development of the products and bring them to market, either independently or in collaboration with the company.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Copenhagen
PEG
Daily low / high price
0.279 / 0.301
DKK
Market cap
296.66M DKK
Turnover
169.89K DKK
Volume
592K
Latest research
Extensive report
Inderes' extensive report is an investor's handbook on customer companies covered by our research.
The latest extensive report was released
Read the reportAnalyst
![Claus Thestrup Claus Thestrup](https://www.inderes.se/cdn-cgi/image/format=auto,width=128,height=128,quality=90,fit=cover/https://content.inderes.se/assets/637ef734-dcbf-426c-bf91-0ac4a79aa71e.png)
Claus Thestrup
CEO, Sweden
Latest videos
Financial calendar
Interim report
16.08.2024
Interim report
15.11.2024
ShowingAll content types
Major shareholder announcement - Pharma Equity Group A/S
Major shareholder announcement - Pharma Equity Group A/S
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
![HCA Capital: Wrap up from 2024 Life Science seminar](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/ab49c0b1-56d0-4e1c-b729-6c79c89b7be2.png)
HCA Capital: Wrap up from 2024 Life Science seminar
![Life Science seminar 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/ab49c0b1-56d0-4e1c-b729-6c79c89b7be2.png)
Life Science seminar 2024
Results of extraordinary general meeting in Pharma Equity Group A/S
![Pharma Equity Group: Investors appreciate eventful, and mostly positive, 1. quarter 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/e63e4a03-8498-4f91-be79-24be09bcc666.png)
Pharma Equity Group: Investors appreciate eventful, and mostly positive, 1. quarter 2024
The Board of Director's decision to issue convertible loans
Consolidated interim report 1 January – 31 March 2024
Exploration of options regarding a directed capital increase at market price in Pharma Equity Group A/S
Notice convening the extraordinary general meeting of Pharma Equity Group A/S
![Pharma Equity Group (One-pager): Continues to move forward but the shares continues to slide](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/e63e4a03-8498-4f91-be79-24be09bcc666.png)